Most hedge funds that specialize in life sciences and biopharma stocks posted strong gains in November, enabling several to move into the black with one month remaining in the year.
In fact, at least five funds generated double-digit returns last month, exceeding the broad market averages, which enjoyed their best month in well over a year.
